Epitopoietic Research Corporation
2 clinical trials · Sponsor
◉ Watch Epitopoietic Research Corporation
| Record | Firm | Date |
|---|---|---|
| ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab (NCT05366062) | Epitopoietic Research Corporation | 2022-07-01 |
Track Epitopoietic Research Corporation automatically
Every clearance here is in the API, with alerts when new ones post.